Rapid, Deepening Symptom Relief Highlighted Out to 48 Weeks
Cogent Biosciences (NASDAQ: COGT) presented new 48-week results for its lead drug bezuclastinib, offering continued optimism for NonAdvanced Systemic Mastocytosis (NonAdvSM) patients. These findings, unveiled at the 2026 AAAAI Annual Meeting, show clear, ongoing improvement in core symptoms and disease biomarkers over nearly a year of treatment—a critical consideration for a chronic, debilitating disease with few options.
Key Outcomes: 99% Achieve Major Tryptase Reduction While TSS Improves by 56%
The SUMMIT trial outcomes reinforce the potential of bezuclastinib as a first-in-class disease modifier. After 48 weeks, patients saw an average Total Symptom Score (TSS) drop of 32.0 points, or a 56% improvement from baseline. Most notably, 99% achieved at least a 50% reduction in serum tryptase (a mast cell activity biomarker) and 83% normalized tryptase levels, both highly promising indicators of effective disease control.
| Metric | Result at 48 Weeks |
|---|---|
| Mean TSS Change | -32.00 points (56% improvement) |
| ≥30% Symptom Improvement | 86% of patients |
| ≥50% Tryptase Reduction | 99% of patients |
| Tryptase Normalization | 83% of patients |
Benefits Extend Across All Core Symptom Domains
Bezuclastinib demonstrated robust and broad impact, with improvements recorded for dermatologic, neurocognitive, GI, pain, and fatigue symptoms. The following table summarizes mean changes and relative improvements for each core symptom domain through 48 weeks:
| Symptom Domain | Mean Change | Relative Improvement |
|---|---|---|
| Dermatologic | -13.94 | -65.0% |
| Neurocognitive | -12.77 | -53.6% |
| Gastrointestinal | -6.63 | -62.5% |
| Pain | -5.43 | -45.8% |
| Fatigue | -3.02 | -41.3% |
Disease Modification Signals: Biomarkers and Bone Health Both Improve
Results go beyond symptoms. The strong correlation between tryptase reduction and TSS improvements, meaningful bone mineral density gains by week 24 (regardless of baseline BMD), and a reduction or discontinuation of supportive medicines by 50% of patients at 48 weeks, indicate a potential shift in disease course—not just symptom management. This is especially notable for the challenging smoldering SM subgroup, which also saw consistent improvement.
Safety Profile & Company Moves: Favorable Support for Chronic Use and New Employee Incentives
The safety and tolerability of bezuclastinib, backed by these ongoing trial results, further support its viability as a chronic therapy for NonAdvSM. In parallel, Cogent also announced inducement grants for three new employees, including options for 24,000 shares and 21,000 RSUs vesting over four years—a move that could reinforce the company’s long-term focus as development continues.
What’s Next? Takeaway for Investors and Patients
While no therapy is a guarantee, these comprehensive 48-week data provide some of the strongest evidence to date that bezuclastinib could change the standard for NonAdvanced SM. Investors and stakeholders will be watching for further peer-reviewed publication, FDA feedback, and any signals about commercial path as these results mature. The latest data is available on Cogent’s website in the Posters and Publications section.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI